Journal of Osteoporosis / 2010 / Article / Tab 3 / Review Article
Progesterone and Bone: Actions Promoting Bone Health in Women Table 3 Double-blind randomized controlled trials of percentage spine Bone Mineral Density (BMD) change per year in postmenopausal women treated with Progesterone/Medroxyprogesterone (MPA) compared with placebo.
Author/year and reference Total number Age Bone site Years Drug and dose Schedule Number % BMD Change (Active) Number % BMD Change (Placebo) Gallagher 1991 [84 ] 81 51.7 ± 4.4 DPA* L2- 4 2 MPA 20 mg 23/28 days 20 Spine - 2.5 20 Spine - 3.8 Radius 20 Radius 0.0 18 Radius - 2.4 Prior 1997 [85 ] 33 45 ± 5 QCT T12- L3 DXA 1 MPA 10 mg Daily 18 QCT - 15 NA ∙ NA WB+ WB - 2.8 NA NA FN+ + FN - 5.2 NA NA Leonetti 1999 [86 ] 102 52.5 DXA L2- 4 1
*
P 4 Cream 20 mg Daily 43 Spine - 1.4 47 Spine - 1.0 T Hip 43 T Hip - 2.5 47 T Hip - 1.0 Liu 2005 [87 ] 132 52.5 DXA L2- 4 2 + OMP300 mg Daily 15 Spine - 1.0 23 Spine - 1.0 FN 15 FN - 0.5 23 FN - 0.0 MPA 10 mg Daily 16 Spine - 1.9 23 Spine - 1.0 16 FN - 1.1 23 FN - 0.0 Mean % Change OMP & P4 Cream 58 Spine - 1.2 70 Spine - 1.0 MPA 36 Spine - 2.2 43 Spine - 2.4
*P4 : progesterone+ OMP: oral micronized progesteroneNA ∙ : not available—this trial was controlled by conjugated equine estrogen and without a placebo.